Cephalon, Inc.
NASDAQ:CEPH ISIN:US1567081096
News
Mesoblast Limited (ASX:MSB) and its strategic alliance partner Cephalon Inc. were today awarded the Licensing Executives Society (U.S.A. and Canada), Inc. 2011 Deals of Distinction(TM) Award. The award was conferred for the most compelling licensing and intellectual property-related deal in the life sciences sector.
Global regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor(TM) is an allogeneic, or "off-the-shelf", adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks.
Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today provided its full year financial results. The company stated that it had substantial funds of A$263.2 million at 30 June 2011. Mesoblast recorded revenue and other income of A$120.9 million and a profit before tax of A$92.2 million.
Global regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration to begin a Phase 3 clinical trial for bone marrow regeneration in patients with blood cancers. FDA clearance was obtained within the 30-day minimum time period after Mesoblast filed its Phase 3 Investigational New Drug submission.
Results from Mesoblast Limited's (ASX:MSB) (PINK:MBLTY) cardiovascular clinical trials were featured at the Goldman Sachs 32nd Annual Global Healthcare Conference in California today.
Mesoblast Limited (ASX:MSB) (PINK:MBLTY) wishes to inform the market that the Board of its strategic partner Cephalon Inc. (NASDAQ:CEPH) has rejected the unsolicited proposal from Valeant Pharmaceuticals International Inc (NYSE:VRX) to acquire its issued share capital or certain assets.
Mesoblast Limited (ASX:MSB) (PINK:MBLTY), has received a number of enquiries from shareholders and analysts regarding yesterday's announcement by Mesoblast's strategic partner Cephalon Inc. (NASDAQ:CEPH) that it had received an unsolicited proposal from Valeant Pharmaceuticals International Inc (TSE:VRX) to acquire Cephalon's issued share capital or certain assets. Mesoblast continues to maintain a close dialogue with Cephalon.
Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today reported its half year results for the period ended 31 December 2010. At the reporting date, Mesoblast recorded funds of $140.6 million but has since nearly doubled its cash reserves to $279 million after an equity purchase by global biopharmaceutical company Cephalon Inc. (NASDAQ:CEPH) that brings its total Mesoblast holding to 19.99%.
Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today reported that it had issued an additional 24,702,056 ordinary shares to global biopharmaceutical company Cephalon Inc. (NASDAQ:CEPH), and received an additional cash injection of A$139 million. Mesoblast's total cash reserves are now approximately A$280 million.
The strategic alliance between regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), and global biopharmaceutical company, Cephalon Inc. (NASDAQ:CEPH), was highlighted at the 29th annual JP Morgan Healthcare Conference in San Francisco yesterday.
10,699 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 26) (Last 30 Days: 70) (Since Published: 10699)